Filtered By:
Specialty: Drugs & Pharmacology
Management: Electronic Medical Records (EMR)
Countries: Spain Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain
ConclusionUp to 82% of patients with atherosclerotic CV disease do not achieve LDL-C levels recommended by the 2019 ESC/EAS guidelines despite being on optimized oral LLT therapy. In 17.9% of these patients LDL-C levels exceed 100 mg/dL, being eligible for PCSK9i in Spain.
Source: Advances in Therapy - December 16, 2022 Category: Drugs & Pharmacology Source Type: research
